Our pipeline:
multiple modalities and novel targets

We are committed to delivering life-changing RNA medicines so that patients and families can realize a brighter future.

Our pipeline is differentiated and diversified, spanning multiple modalities including RNA editing, splicing and silencing, as well as several disease areas.

Through GSK collaboration, Wave can advance up to three collaboration programs and GSK can advance up to eight collaboration programs

AATD: Alpha-1 antitrypsin deficiency; DMD: Duchenne muscular dystrophy; HD: Huntington's disease; SCA3: Spinocerebellar ataxia 3

RNA Editing

WVE-006

SERPINA1 (AATD)

Multiple

Splicing

WVE-N531

Exon 53 (DMD)

Other exons (DMD)

SILENCING: ANTISENSE

WVE-003

mHTT (HD)

SCA3 (ATXN3)

SILENCING: RNAi

Multiple

Through GSK collaboration, Wave can advance up to three collaboration programs and GSK can advance up to eight collaboration programs

AATD: Alpha-1 antitrypsin deficiency; DMD: Duchenne muscular dystrophy; HD: Huntington's disease; SCA3: Spinocerebellar ataxia 3

Cancel Continue